Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination

Bristol-Myers Squibb Company (NYSE:BMY) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 3, Arcus Biosciences announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE:BMY), where Arcus’s investigational kidney cancer drug, casdatifan, will be added to Bristol-Myers’s ongoing Phase 1/2 ROSETTA RCC-208 trial. The trial focuses on pumitamig, an investigational bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb targeting patients with advanced renal cell carcinoma (RCC).

Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination

Arcus said that it will supply casdatifan for use in two new treatment arms that will be added to the existing ROSETTA RCC-208 trial structure. However, both companies retain full development and commercial rights to their respective drugs.

Arcus CEO Terry Rosen, Ph.D., noted that this collaboration with Bristol-Myers is strategic and that it is “a top priority for Arcus in order to potentially deliver an additional effective TKI-free option in the first-line setting.”

Separately, on June 8, Bristol-Myers launched “Investigating Myeloma”, a multiple myeloma awareness campaign in partnership with actress and advocate Mariska Hargitay. Hargitay is best known for her 27-year run as Detective Olivia Benson on Law & Order: SVU, and she lost her father to the disease 20 years ago.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, immunology, cardiovascular, and neuroscience.

While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Stocks to Buy Now for Good Returns and 10 Best Growth Stocks to Buy According to Billionaire Dan Loeb.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1